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Introduction
It has been over twenty years since the onset of the 
AIDS epidemic, and in spite of the tremendous prog-
ress made towards the understanding of the disease, 
the virus that causes the disease and the development 
of highly effective anti-retroviral treatments, the num-
ber of people infected by HIV is still staggering. As 
of the end of 2004, it was estimated that there were 
39.4 million people newly infected with HIV, and 3.1 
million deaths globally (www.UNAIDS.org). Over 
2/3 of infections occur in the developing world and 
sub-Saharan Africa. Concurrent with immunosup-
pression in the infected individuals are opportunis-
tic infections and AIDS-associated diseases, includ-
ing malignancies, which have increased substantially 
during the AIDS disease course [1, 2]. Malignancies 
that were found to have high incidence of HIV-in-
fected individuals are Kaposi’s sarcoma (KS), Hodg-
kin’s disease (HD), non-Hodgkin’s lymphoma (NHL), 
squamous cell carcinomas, plasmacytomas, and leio-
myosarcoma in children. These tumors arose due to 
the lack of appropriate immune response or the reac-
tivation of etiological agents associate with these tu-
mors in immunosuppressed HIV infected individuals. 
Serveral AIDS-associated malignancies were found to 
be associated with the viral infections. Among them, 
Epstein-Barr virus (EBV) was found to associate with 
NHL, HD, and leiomyosarcoma; Kaposi’s sarcoma as-
sociated herpesvirus (KSHV) or human herpesvirus-8 
(HHV-8) was found to associate with KS and primary 
effusion lymphoma (PEL), and human papilloma vi-
rus (HPV) was found to associate with squamous cell 
neoplasia. The most common malignancies seen in 
HIV-infected individuals are KS and HNL, and both 
have been classified as AIDS defining illnesses.
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Abstract
AIDS associated malignancies (ARL) is a major complication associated with AIDS patients upon immunosuppres-
sion. Chronically immunocompromised patients have a markedly increased risk of developing lymphoproliferative 
disease. In the era of potent antiretrovirals therapy (ARV), the malignant complications due to HIV-1 infection have 
decreased in developed nations where ARV is administered, but still poses a major problem in developing countries 
where HIV-l incidence is high and ARV is still not yet widely available. Even in ARV treated individuals there is a con-
cern that the prolonged survival of many HIV-l carriers is likely to eventually result in an increased number of malig-
nancies diagnosed. Malignancies that were found to have high incidence in HIV-infected individuals are Kaposi’s sar-
coma (KS), Hodgkin’sdisease (HD) and non-Hodgkin’s lymphoma (NHL). The incidence of NHL has increased nearly 
200 fold in HIV-positive patients, and accounts for a greater percentage of AIDS defining illness in the US and Europe 
since the advent of HAART therapy. These AIDS related lymphomas are distinct from their counterparts seen in HIV-l 
seronegative patients. For example nearly half of all cases of ARL are associated with the presence of a gamma herpes-
virus, Epstein Barr virus (EBV) or human herpesvirus-8 (HHV-8)/Kaposi’s sarcoma associated herpesvirus (KSHV). 
The pathogenesis of ARLs is complex. B-cell proliferation driven by chronic antigenemia resulting in the induction of 
polyclonal and ultimately monoclonal lymphoproliferation may occur in the setting of severe immunosuppression.
Keywords: Kaposi’s sarcoma, lymphomas, Epstein-Barr virus, KS-associated herpesvirus, human herpesvirus 8.
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decreased in developed nations where potent anti-
retrovirals (ARV) are widely available. However, the 
prolonged survival of many HIV carriers is likely to 
eventually result in an increased number of malignan-
cies diagnosed in these individuals. Chronically immu-
nocompromised patients have a markedly increased 
risk of developing lymphoproliferative disease. The 
incidence of non-Hodgkin’s lymphomas (NHL) is in-
creased nearly 200 fold in HIV-positive patients and 
accounts for a greater percentage of AIDS defining ill-
ness in the US since the advent of HAART therapy [3, 
4]. AIDS related lymphomas (ARLs) are distinct from 
their counterparts seen in HIV seronegative patients. 
For example nearly half of all cases of ARL are associ-
ated with the presence of a gamma herpesvirus, EBV 
or HHV-8 [5]. ARLs are often diagnosed at a very ad-
vanced stage and frequently involve uncommon sites 
(oral cavity, GI tract, central nervous system) [5, 6]. The 
pathogenesis of ARLs is complex. B-cell proliferation 
driven by chronic antigenemia results in the induction 
of polyclonal, and ultimately monoclonal lymphopro-
liferation. In addition, dysregulation of cytokine path-
ways (interleukin-6 and interleukin-l0), coupled with 
bcl-6, p53, and c-myc mutations have been implicated 
in the pathogenesis of ARL [7].
Subtypes of AIDS NHLS
AIDS NHLs may be broadly categorized into several 
subtypes. Large cell immunoblastic lymphoma (IBL) 
and diffuse large cell lymphoma (DLCL) generally oc-
cur inthe setting of moderate to severe immunosup-
pression (CD4+ lymphocyte counts below 100 mm3/
ml). IBLs and, to a lesser degree, DLCLs are often as-
sociated with EBV. These tumors express the EBV en-
coded oncoprotein latent membrane protein-l (LMP-l) 
[5-7]. LMP-l may function in a similar manner to tu-
mor necrosis factor receptors by activating cellular 
anti-apoptotic factors such as Nuclear Factor Kappa B 
[6, 7]. DLCLs are frequently found to contain genetic 
alterations in Bcl-6 [8] although the consequences of 
these mutations have not been fully defined.
AIDS related Burkitt’s lymphoma (BL) generally oc-
curs in more immunocompetent patients [9]. AIDS 
BLs share features with endemic African BL in that 
both overexpress c-myc due to reciprocal transloca-
tions that bring the transactivator under the influ-
ence of potent promoter sequences within the immu-
noglobulin (Ig) genes loci. Inactivating mutations and 
deletions of p53 are also common as in all types of BL 
[10]. A distinguishing feature between AIDS related 
and endemic BL is that the former is associated with 
EBV far less frequently than the latter [9, 10]. These 
tumors are incredibly aggressive with brief doubling 
times. Flow cytometric analysis typically reveals that 
over 90% are in S phase. Ongoing tumor lysis syn-
drome even in the absence of concomitant chemother-
apyis often noted. AIDS related BLs appear to carry a 
poor prognosis even when compared to AIDS related 
DLCL [11].
A recently described variant of ARL, plasmablastic 
lymphoma, occurs in a small percent of HIV+ patients. 
These tumors are generally associated with EBV and 
HHV8 (10). Response to conventional chemotherapy 
is poor and some investigators have suggested that vi-
ral targeted approaches may be beneficial [12].
A rapidly fatal subtype of AIDS NHL is Primary 
Central Nervous System Lymphoma (PCNSL). These 
tumors aremost frequently classified as IBLs and oc-
cur in the most immunosuppressed patients. In con-
trast to PCNSL in HIV-negative patients they are vir-
tually always associated with EBV [13]. Detection of 
EBV sequences in the CSF by polymerase chain reac-
tion (PCR) coupled with positive Thallium spectros-
copy has proven to be a helpful diagnostic tool [14]. 
These patients are often afflicted by many complica-
tions of HIV infection. Standard therapy with conven-
tional chemotherapy combined with radiation therapy 
results in only about a 4 month survival although long 
term remission has been reported in patients treated 
with high dose Zidovudine and Ganciclovir [15, 16].
The most commonly identified virus associated with 
AIDS related lymphomas is EBV and there is a large 
body of published work on the oncogenic mechanisms 
of this agent [17, 18]. B-lymphocytes transformed by 
EBV (lymphoblastoid cell lines) in vitro express an ar-
ray of virus-encoded proteins including six EBV nu-
clear antigens (EBNAs) and three LMPs. EBNAs are 
generated from differential splicing of a transcript 
that arises from one of two promoters (Cp or Wp) [18]. 
This form of latency is termed Latency III. This form 
of latency is common inimmunoblastic lymphomas 
[17]. A Type II form of latency where EBNA 1, LMP-l 
and LMP-2a are expressed has been identified in some 
EBV associated lymphomas. In Latency I (typical of 
Burkitt lymphomas) only EBNA-l (generated from the 
Qp promoter) and EBERs are expressed [17, 18]. Re-
cent studies have indicated that some heterogeneity in 
EBV gene expression and EBNA promoter usage ex-
ists among endemic BL [19].
Therapy of AIDS NHL
Treatment of the AIDS NHL remains disappointing. 
Polychemotherapy regimens have produced similar re-
sults although regimens that combine potent antiretro-
virals with conventional chemotherapy may prove su-
perior [20]. HIV-positive patients often have poor bone 
marrow reserve which compromises the ability to de-
liver full dose chemotherapy. Concomitant opportu-
aidS a n d aS S o c i a t e d Ma l i g n a n c i e S  949
nistic infections may also lead to a decrease in chemo-
therapy delivery. In general, response and survival 
rates for common NHL regimens are lower than for 
an HIV-negative population. Complete responses oc-
cur but tend to be of shorter duration with frequent re-
lapses. Our experience has been that patients concom-
itantly diagnosed with HIV infection and lymphomas 
do better with antiretroviral and anti-lymphoma ther-
apy than do those who develop lymphoma after be-
coming refractory to antiretrovirals. A recently com-
pleted study performed by the NCI-sponsored AIDS 
malignancy consortium (AMe) demonstrated the feasi-
bility of concomitant chemotherapy with HAART [21]. 
Probably the best reported results for chemotherapy in 
AIDS NHL were from Dr. Little’s group at the National 
Cancer Institute. Using the EPOCH regimen, the group 
achieved remission in 22 of 24 patients with a progres-
sion free survival of 23 months. These patients had fa-
vorable prognostic factors (median CD4+ lymphocyte 
count of 233 mm3/ml) [20]. Enhanced toxicity of ritux-
imab and CHOP chemotherapy was recently noted in a 
large multi-center trial conducted by the AMC [22]. The 
addition of rituximab to standard-dose CHOP as com-
pared to CHOP alone led to increased infectious com-
plications and deaths attributable to sepsis. It ispossible 
that delayed recovery of humoral immunity could con-
tribute to this increased risk of life-threatening bacterial 
infections in HIV-infected patients. There have been 
several reports on the feasibility and efficacy of high 
dose chemotherapy and autologous stem cell trans-
plant for ARL [23, 24]. It is reasonable to assume that pa-
tients with well controlled HIV and good performance 
status should be considered candidates for this ther-
apy. Newer approaches that may benefit patients with 
ARL include EBV specific cytotoxic T cells and agents 
that activate the lytic program of gamma herpesviruses 
thereby sensitizing the tumors to antivirals [25, 26].
Kaposi’s Sarcoma
Kaposi’s sarcoma was first described by Moritz Ka-
posi in 1872 in several cases of multi-focal pigmented 
sarcoma in elderly Mediterranean men. There are four 
forms of KS. The first is known as the classic KS or spo-
radic KS. They are mainly found in the elderly male 
population in Mediterranean countries, such as Italy 
[28]. The lesions tend to be found in the lower extrem-
ities and are generally non-aggressive. The second 
type is known as the endemic African KS; it is more 
aggressive than the classic KS and can also involve the 
lymph nodes. This form of KS was seen in the African 
continent prior to the HIV epidemic and was found in 
adults (both male and female) and in children [29]. The 
third is the iatrogenic form of KS, which normally oc-
curs after transplantation in patients treatedwith im-
munosuppressive medication. This form of KS seems 
to vary in geographical prevalence, and is more com-
mon in individuals of Mediterranean descent [30]. 
The fourth form of KS is the AIDS-KS. This is a very 
aggressive type of KS, first described in early 1980’s 
in homosexual men [31]. AIDS-KS not only involves 
skin, but also the lymph nodes and often dissemi-
nates to lungs, gastrointestinal tract, liver, and spleen.
KS is composed of a mixture of irregular shaped, 
round capillaries, and slit-like endothelium-lined 
vascular spacesand spindle-shape cells with infil-
trating mononuclear cells. It is not clear whether KS 
represents a clonal neoplasticprocess or a polyclonal 
inflammatory lesion. Studies have shown that varying 
monclonality, oligoclonality, and polyclonality from 
lesions of various patients [32]. The origin of the KS 
spindle cells is also not clear; it has been suggested that 
KS cells represent a heterogeneous populationof cells, 
arising from a pluripotent mesenchmal precursor cells, 
and may be of lymphatic endothelial cell origin [33].
Human Herpesvirus and KS
An infectious agent has long been suspected in the 
development of KS; herpesvirus-like particles were 
found in short-term KS tissue culture, and were sub-
sequently identified as cytomegalovirus [34], but the 
involvement of CMV in KS has not been confirmed. 
In 1994, a novel humanherpesvirus was identified by 
Chang and Moore [35] using representational differ-
ence analyses. This virus is now known as KSHV or 
HHV-8, it is found to be necessary but not sufficient for 
the development of all types of KS. It is clear that other 
co-factors, such as immunosuppression, are required 
for KS development. KSHV is found in all KS lesions, 
and is mainly located in the vascular endothelial cells 
and perivascular spindle-shaped cells [36]. KSHV in-
fection is not commonly found in low-risk popula-
tion but found commonly in individuals at risk for KS.
KSHV belongs to the γ-herpesvirus family, which can-
further be divided into two subgroups, y-l or lymphocry-
tovirus and γ-2 or rhadinovirus. EBV is the prototype 
of γ-l virus and the simian herpesvirus saimini isthe 
prototype of γ-2 herpesvirus [37]. KSHV is classified as 
a γ-2 rhadinovirus and is the first human virus of this 
subfamily identified. Like other herpesviruses, HHV-8 
is a double-stranded deoxyribonucleic acid (DNA) vi-
rus. Its genome is linear, is about 165 kbp in length, and 
containsat least 87 viral genes. A feature of some DNA 
viruses, particularly of herpesviruses and KSHV, is the 
ability of these viruses to incorporate or pirate host genes 
into their genome: these genes can then play a role in 
the replication, survival, and transformation functions 
of the virus. KSHV was found to encode human ho-
mologue genes that regulate cell cycling like cyclin D, 
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growth factors like interleukin 6, or genes that may pre-
vent programmed cell death such as bcl-2. Deciphering 
the functions of these viral genes will lead to a better 
understanding of viral pathogenesis and oncogenesis.
Unlike most other herpesviruses, KSHV infection 
does not seem to be widely distributed in most popu-
lations. The detection of KSHV infection relies on the 
presence of antibodies against either lytic and/or la-
tent antigens and varies among the different tests that 
were used in different seroprevalence studies. In gen-
eral, the frequency of infection appears to be low in 
North America, certain Asian countries, and in North-
ern European nations such as the United Kingdom 
and Germany, with most studies reporting a sero-
prevalence rate in normal blood donors of less than 
5% [2, 38-40]. In these countries the seroprevalence of 
KSHV in different risk groups mirrors the incidence 
of AIDS KS, with a seroprevalence rate ofbetween 
25-50% among homosexual men. In other countries 
such as Italy, Greece, and Israel, especially South-
ern Italy, the infection rate seems to be much higher 
in the general population, and is more variable, rang-
ing between 5-35%. In contrast to North America and 
Europe, KSHV infection is widespread in the Afri-
can continent. High seroprevalence rates between 40 
to 50% have been found in Central, West, as well as 
South Africa [41-44]. Therefore, KSHV seroprevalence 
tracks very closely with KS, with the highest infec-
tion rate in geographic areas where classic or endemic 
forms of KS are more common. KS has a particularly 
high incidence in Central African countries like the 
Republic of Congo, Uganda, and Zambia; these coun-
tries also have the highest KSHV infection rates in the 
world [42]. Very little is known about KSHV infection 
in China even though EBV infection was found to be 
ubiquitous. There were only two reported studies in 
China; the study by Dilnur et al. [45] found that KSHV 
was associated with KS in China. The study by Du et al. 
[46] in the outskirts of China in the Xinjiang autonomy 
region, where there is a high incidence of HIV-1 infec-
tion, showed that there was a high HHV-8 infection 
rate. The study found KSHV infection varied among 
individuals of different racial origin, it was highest in 
the Khalkhas population at about 48% and lowest in 
the Kazak and Han population at over 12%, but the 
specimens were screened without dilution and the re-
producibility of the assay was not determined, and 
theprevalence among different risk groups was not 
studied. Thus, there is a need to perform a systematic 
comparison of risk groups using established assays.
Primary Effusion Lymphomas
In addition to KS, KSHV has also been associated with 
several other AIDS-associated neoplasms, primary ef-
fusion lymphomas, and multi-centric Castleman’s dis-
ease. Primary effusion lymphoma (PEL) was first iden-
tified as a subset of body-cavity-based lymphomas, 
which subsequently was called PELs [47]. PELs are 
unique as they were found to contain KSHV DNA are 
most frequently found in men and in AIDS patients. 
This type of lymphoma is distinguished from others 
as having a distinctive morphology, bridging large 
cell immunoblastic lymphoma and anaplastic large 
cell lymphoma. PELs often present as lymphomatous 
effusions in the pleural, peritoneal, and/or pericardial 
cavity. These cells are usually CD20 negative but often 
express CD45 marker but lack B-cell-associated anti-
gens. PELs are B cell origin with clonal immunoglob-
ulin gene rearrangements. Most PELs are co-infected 
with EBV and lack e-myc gene rearrangements. PELs 
are extremely rare tumors, and estimated to be about 
0.13% of all AIDS-related malignancies in AIDS pa-
tients in the US [48]. Thus, KSHV-associated lympho-
mas represent a rare, distinct pathobiologic category 
which often, but not always, associates with an effu-
sion in AIDS patients. The role of KSHV in the devel-
opment of these lymphomas is not clear since this type 
of malignancy is still rare even in the populations with 
high KSHV seroprevalence rate. However, KSHV has 
always been found in these lymphomas, suggesting 
that this virus is necessary, but other factors must be 
needed for the development of PELs. These factors 
could be EBV infection and/or immunosuppression. 
Recently solid tumor variants with plasmablastic fea-
tures have been reported and these tumors tend to be 
rapidly fatal although recent data suggests that some 
PEL lines are quite sensitive to inhibition of NF-KB [49].
Multi-centric Castleman’s Disease
Multi-centric Castleman’s disease (MCD) has also 
been associated with KSHV infection. MCD is a rare 
and poorly understood B cell lymphoproliferative dis-
order with vascular proliferation in the germinal cen-
ters, and is though to be related to immune dysregu-
lation [50]. KSHV is found in almost all cases of MCD 
in AIDS patients and in about 50% of cases of MCD in 
HIV-negative individuals, suggesting that there is an 
association between KSHV and MCD at least in HIV-
positive cases [51]. However, the role of KSHV in the 
pathobiology of MCD is not well understood, and it is 
not clear whether there are any clinical differences be-
tween those with and without KSHV.
Impact of HAART on KS
Since the beginning of the AIDS epidemic in the early 
1980’s, AIDS-KS has become one of the most common 
AIDS-associated malignancies with HIV-infected ho-
mosexual males at the highest risk, and those with 
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AIDS had a 50% lifetime rate of developing KS early in 
the HIV epidemic [52]. However, the rate of AIDS-KS 
has since steadily declined both in the US and Europe 
[53]. It has been suggested that the disease may have 
shifted from an early disease to a late manifestation 
during the HIV disease course. Since the introduction 
of highly active antiretroviral therapy, a further major 
decrease in AIDS-KS was further observed [54], and 
therapy has now made AIDS-KS a relatively rare tu-
mor in treated HIV-infected individuals [55]. Several 
studies have shown that there was a marked decrease 
in KS incidence since HAART was introduced, a de-
cline of as high as 80-fold was observed. In addition re-
gression of KS following treatment has been reported 
[4, 56-59]. Interestingly, the reduced KS risk was only 
observed with HAART, but not with double or single 
anti-HIVdrugs [60]. Even though the incidence of KS 
in the treated HIV-infected individuals in the western 
world has decreased dramatically, in the setting where 
HAART is still not widely available, such as sub-Sa-
haran Africa, AIDS-KS still remains a major problem.
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